Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer
Drug Resistance Updates · 2026-03 · 85 · 101354
DOI: 10.1016/j.drup.2026.101354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-03. Verfasst von Marco Pieraccioli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, Rome 00168, Italy; GSTeP Organoids Research Core Facil…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Organoids, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca, Ministero dell'Istruzione dell'Universita e della Ricerca, Ministry of Health.
Abstract (Originalsprache)
AIM: High grade serous ovarian cancer (HGSOC) is the most aggressive subtype of ovarian cancer. HGSOC is characterized by high inter- and intra-tumoral heterogeneity, which contributes to chemotherapy resistance. Patient-derived organoids (PDOs) are valuable preclinical models to elucidate the biology of human cancers and to test their response to treatments. This study aims at characterizing the cellular heterogeneity of PDOs and to uncover vulnerabilities of chemotherapy resistant HGSOC. METHODS: Single-cell transcriptomics of PDOs developed from biopsies of platinum-resistant and platinum-sensitive HGSOC. Chemotherapeutic treatments of HGSOC PDOs and of ascitic-derived ovarian cancer cells and immunohistochemistry analyses of tissues from independent HGSOC patients. RESULTS: HGSOC PDOs comprise subclusters of cells exhibiting different transcriptional states and patient-specific signatures. Proliferative and non-proliferative subclusters co-exist in PDOs and their relative proportion is altered by chemotherapy. Proliferative cell sub-populations exhibit expression of cell cycle and DNA damage response related genes, whereas non-proliferative sub-populations display inflammatory signatures. Furthermore, sensitivity to platinum-based treatments was inversely correlated with oxidative phosphorylation (OXHPOS) in PDOs, indicating a metabolic switch associated with chemoresistance. Accordingly, platinum-resistant PDOs and ascitic HGSOC cells show higher sensitivity to OXHPOS inhibition. We found that neoadjuvant chemotherapy (NACT) directly up-regulates oncogenic and metabolic pathways that are involved in development of recurrence, such as the MYC and OXPHOS genes. NACT also induces the expression of major histocompatibility complex type II (MHC-II) molecules. Immunohistochemistry confirmed MHC-II up-regulation in post-NACT biopsies, indicating that tumour cells mount a general antigen-presenting response upon chemotherapy, associated with recruitment of infiltrating immune cells. CONCLUSION: PDOs maintain the inter- and intra-tumoral cellular heterogeneity of HGSOC. Chemotherapy targets proliferative cell subclusters, sparing non-proliferative ones. Dependency on OXPHOS represents an actionable vulnerability in PDOs, which can be exploited to hijack chemoresistance. Sequential chemotherapy and immunotherapy may also improve clinical response of HGSOC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, Rome 00168, Italy; GSTeP Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, Rome 00168, Italy.
- GSTeP Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, Rome 00168, Italy.
- Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome 00168, Italy.
- Gynecopathology and Breast Pathology Unit, Department of Women, Children and Public Health Sciences, Fondazione Policlinico A. Gemelli IRCCS, Rome 00168, Italy.
- Departmental Unit of Molecular and Genomic Diagnostics, GSTeP Genomics Core Facility, Fondazione Policlinico A. Gemelli IRCCS, Rome 00168, Italy; Clinical Chemistry, Biochemistry and Molecular Biology Operations (UOC),…
- Clinical Chemistry, Biochemistry and Molecular Biology Operations (UOC), Fondazione Policlinico A. Gemelli IRCCS, Rome 00168, Italy; Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinic…
Förderung
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Ministero dell'Istruzione dell'Universita e della Ricerca
- Ministry of Health
- Italian Association for Cancer Research
- Catholic University of the Sacred Heart
Zitieren
APA
Pieraccioli, M., Ciucci, A., Corti, C., Mastrantonio, R., Scarpone, E. K., Cesari, E., Piermattei, A., Minucci, A., Urbani, A., Camarda, F., Fagotti, A., Tamagnone, L., Scambia, G., Nero, C., & Sette, C. (2026). Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer. Drug Resistance Updates, 85, 101354. https://doi.org/10.1016/j.drup.2026.101354
Vancouver
Pieraccioli M, Ciucci A, Corti C, Mastrantonio R, Scarpone EK, Cesari E, et al. Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer. Drug Resistance Updates. 2026;85:101354. doi:10.1016/j.drup.2026.101354
BibTeX
@article{Pieraccioli2026,
author = {Pieraccioli, Marco and Ciucci, Alessandra and Corti, Christian and Mastrantonio, Roberta and Scarpone, Eleonora Kristina and Cesari, Eleonora and Piermattei, Alessia and Minucci, Angelo and Urbani, Andrea and Camarda, Floriana and Fagotti, Anna and Tamagnone, Luca and Scambia, Giovanni and Nero, Camilla and Sette, Claudio},
title = {Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer},
journal = {Drug Resistance Updates},
year = {2026},
volume = {85},
pages = {101354},
doi = {10.1016/j.drup.2026.101354}
}
EUVIMED